Steven Cohen’s Syndax Pharmaceuticals SNDX Stock Holding History

Steven Cohen’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-200,000	Closed	-$2.46M	–	2582
2025 Q1	$2.46M	Buy	200,000 +68,600	+52%	+$968K	0.01%	1182
2024 Q4	$1.74M	Buy	+131,400	New	+$2.25M	﹤0.01%	1292
2024 Q3	–	Sell	-62,500	Closed	-$1.28M	–	2314
2024 Q2	$1.28M	Buy	+62,500	New	+$1.31M	﹤0.01%	1208

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Steven Cohen's SNDX Position: Q2 2026 in Review

Steven Cohen sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 1,985,547 shares — an estimated $46.4M sold.

Steven Cohen first reported a position in SNDX in Q1 2017 and held it in 24 quarters. The position peaked at $103M in Q4 2025. 240 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Steven Cohen reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Steven Cohen sold 1,985,547 Syndax Pharmaceuticals shares in Q2 2026, an estimated $46.4M.
Steven Cohen first reported a position in Syndax Pharmaceuticals in Q1 2017 and held it in 24 quarters.
Steven Cohen's Syndax Pharmaceuticals position peaked at $103M in Q4 2025.
240 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.